Inclusion Criteria:

          -  Patients must have a confirmed heterozygous TET2 mutations identified by next
             generation targeted deep sequencing.

          -  Patients must have MDS, or MDS/MPN overlap defined by 2016 World Health Organization
             (WHO) criteria. Both newly diagnosed or previously treated MDS or MDS/MPN patients are
             eligible as long as the patient has never received prior treatment with azacitidine or
             decitabine.

          -  Patients with Leukemic/blast phase transformation MPN.

          -  Patient with AML according to 2016 WHO criteria.

               -  Newly diagnosed patients who are ineligible or declined to receive intensive
                  chemotherapy after discussion of risks and benefits of that approach or patients
                  with primary refractory/relapsed AML.

               -  Patients with active central nervous system (CNS) leukemia eligible at the
                  discretion of treating physician.

               -  Relapse/Refractory is defined as at least 1 course of treatment for AML excluding
                  any patients treated with azacitidine or decitabine.

                    -  Patients should be off any prior treatment or line of therapy for 2 weeks
                       prior to start study with the exception of hydrea (Hydroxyurea).

          -  Prior therapy with hydroxyurea, biological or targeted therapy (e.g. flt3 inhibitors,
             other kinase inhibitors) or hematopoietic growth factors is allowed.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.

          -  Patients must have normal organ and marrow function as defined at the discretion of
             the treating physician and PI.

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 10-14 days prior to enrollment.

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document.

          -  Patient must be willing to comply with all aspects of the protocol including
             completing the drug diary.

          -  Patient must discontinue any and all use of multivitamin and/or vitamin c medication
             24 hours before first dose of Ascorbic Acid.

        Exclusion Criteria:

          -  Any prior treatment with azacitidine or decitabine.

          -  Patients diagnosed with acute promyelocytic leukemia (APL), AML-M3.

          -  Patients receiving other active treatment for their myeloid malignancy including
             investigational agents with the exception of hydrea for white blood cell control.

          -  Nursing or pregnant women.

          -  History of allergic reactions to either azacitidine or ascorbic acid.

          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements.

          -  Patients with higher risk of bleeding (deemed by the treating physician) or on
             anticoagulation.

          -  Patients who are unwilling or unable to comply with all study requirements.